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Eliciting cytotoxic T lymphocytes against
human laryngeal cancer-derived antigens:
evaluation of dendritic cells pulsed with a
heat-treated tumor lysate and other antigen-
loading strategies for dendritic-cell-based
vaccination
Fan-Qin Wei1,2,3†, Wei Sun1†, Thian-Sze Wong4, Wei Gao4, Yi-Hui Wen1,2, Jia-Wei Wei1,2, Yi Wei1,2
and Wei-Ping Wen1,2*
Abstract
Background: Dendritic cells (DCs) have been used successfully in clinical pilot studies. However, tumor-specific
immunity and clinical responses were only induced in certain cancer patients. It has been well documented that
immunotherapy efficacy can be optimized for responses using antigen pulsing.
Methods: The human laryngeal squamous cell cancer (LSCC) cell line SNU899 was used to evaluate the in vitro
anti-tumor efficacy of three different preparations of dendritic cell (DC) vaccines consisting of either whole tumor
cells or their derivatives including: i) DCs pulsed with a tumor cell supernatant (DC-TCS), ii) DCs pulsed with whole-cell
tumor stressed lysate (DC-TSL), and iii) DCs pulsed with irradiated tumor cells (DC-ITC).
Results: Our results showed that DC-TSL is an effective source of tumor-associated antigens (TAAs) for pulsing DCs.
DC-TSL induced the highest expansion of TAA-specific T cells, the strongest Th1 cytokine response, and the most
potent cytotoxic T lymphocyte (CTL) activity. DC-TCS and DC-ITC inhibited T cell activation but induced a certain extent
of CTL activity.
Conclusions: These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal
cancer than other antigen-loading strategies using whole tumor cell materials. This strategy provides an alternative
approach for DC-based immunotherapy for laryngeal cancer.
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Background
Each year, more than 500,000 cases of head and neck
squamous cell carcinoma (HNSCC) are diagnosed world-
wide [1]. Laryngeal squamous cell carcinoma (LSCC)
accounts for a large proportion of HNSCCs [2]. Despite
the rapid development of diagnosis and treatment of
LSCC, including surgery, chemotherapy, and radiotherapy,
the 5-year overall survival rate of LSCC remains relatively
low [3]. The high rate of local recurrence and considerable
mortality that accompany this malignancy mandate the
development of novel therapeutic alternatives.
Immunotherapy is regarded as a promising strategy
that complements current cancer therapies [4]. Dendritic
cell (DC)-based vaccination trials have been performed
for some advanced cancers, such as melanoma and colon,
renal, and prostate cancers [5–7]. They have proven to be
feasible and safe, and to elicit immunological responses
[8]. Current vaccination strategies include antigen (Ag)-
defined vaccines (peptide, DNA, and recombinant tumor
proteins) and polyvalent undefined vaccines (tumor lysate,
heat shock proteins (HSPs), whole tumor cells, and whole
tumor RNA) [5,6]. The former type of vaccine is prepared
using a single tumor-associated antigen (TAA). However,
its application using specific peptides is limited to patients
expressing tumor-associated MHC class I restricted pep-
tides that fail to elicit MHC class II and CD40L-mediated
CD4+ T cell helper responses. In contrast, the latter type
of vaccine, generated using whole tumor cells or their
derivatives, are advantageous in that they provide a full
complement of TAAs, including both MHC class I and
class II-restricted epitopes, thus reducing the risk of
immune escape by antigen loss variants.
Whole tumor cell Ag-loading strategies for DC-based
vaccination have commonly used freeze-thawed tumor cell
lysates as an immunogenic source of TAAs [9, 10]. How-
ever, DCs loaded with such lysates have provided only
modest protection in various animal models [9, 11, 12]
and stimulated limited responses in a range of clinical
trials [10, 13, 14]. Some studies have even shown that
freeze-thawed lysates suppress DC maturation and func-
tions in vitro, and are an ineffective loading strategy for
DC therapy in vivo [15, 16].
To enhance antitumor immunity, studies have attempted
to optimize antigen loading. Compared with ordinary
lysates obtained by subjecting tumor cells to several freeze
(liquid nitrogen) and thaw (37 °C water bath) cycles,
stressed lysates prepared from heat-treated (≥42 °C) tumor
cells are a more effective source of TAAs for pulsing DCs.
Heat-treated tumor lysate-pulsed DCs generate a stronger
and broader T cell response against pancreatic cancer [17].
Irradiated tumor-primed DCs provide more potent pro-
tection against solid tumors, such as human melanoma
[15]. Even retinoblastoma cell supernatants exert an
immunostimulatory effect on DCs [18]. Because differ-
ent tumor strains have various immunogenicities, it
remains uncertain which Ag-loading strategy has super-
ior efficacy for treating human laryngeal carcinoma.
In this study, we performed a detailed examination of
DC phenotypes loaded with TAAs, including a tumor
supernatant (TCS), tumor-stressed lysate (TSL), and
irradiated tumor cells (ITC). Subsequently, we assessed
TAA-specific T cell proliferation and Th1 cytokine pro-
duction induced by these Ag-loaded DCs. Lastly, we
compared the in vitro cytotoxic T lymphocyte (CTL)
responses. Our study identified the human LSCC cell
line SNU899-derived TSL as an efficacious source of
TAAs for pulsing DCs to induce a more potent CTL
response against laryngeal cancer.
Methods
LSCC cell line
SNU899 cells were kindly provided by Professor Ja-Lok
Ku (Seoul National University College of Medicine,
South Korea). Cells were maintained in RPMI-1640 con-
taining 10 % fetal bovine serum, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Sigma, St. Louis, MO,
USA) in a humidified incubator at 37 °C with 5 % CO2.
Ethics statements
The study protocol (No. 2012–349) was approved by The
First Affiliated Hospital of Sun Yat-sen University Ethics
Committee, and was used for research purposes only.
Donor informed consent was obtained before enrollment.
DCs
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy individuals by Ficoll-Hypaque density
gradient centrifugation. CD14+ cells were purified using a
magnetic bead-conjugated mouse anti-human CD14
monoclonal antibody (CD14 MicroBeads, Miltenyi Biotec,
Bergisch Gladbach, Germany). The purity of CD14+ cells
was consistently more than 95 %. Cells were seeded into
six-well plates at 1.5 × 106 cells/well in 2.5 ml RPMI-1640
medium supplemented with 10 % heat-inactivated FBS,
50 ng/ml granulocyte macrophage-colony stimulating fac-
tor (GM-CSF, PeproTech, Rocky Hill, NJ, USA), 20 ng/ml
interleukin (IL)-4 (R&D Systems, Minneapolis, MN,
USA), 100 U/ml penicillin, and 100 μg/ml streptomycin,
and incubated at 37 °C in a humidified atmosphere with
5 % CO2. Half-volume medium changes were per-
formed every 3 days. On day 7, DC maturation was in-
duced by addition of 1 μg/ml lipopolysaccharide (LPS,
Sigma) for an additional 2 days for in vitro experiments.
DC phenotypes were determined by flow cytometry.
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DC loading with SNU899 LSCC-derived Ags
Day 6 DC cultures were loaded with SNU899-derived
Ags using three methods. (1) Pulsing with a tumor cell
supernatant prepared by seeding 4.5 × 106 cells in a T75
flask (Eppendorf, Hamburg, Germany) containing 4.5 mL
completed medium for 24 h, followed by centrifugation to
remove cell debris. (2) Pulsing with a whole-cell TSL pre-
pared at a concentration of 4.5 × 106 cells/well in 0.5 ml
RPMI-1640 medium and heat-treated at 42 °C and 60 °C in
sequence for 1 h each in a thermostatically controlled water
bath, followed by immediate freezing in liquid nitrogen for
10 min and thawing at room temperature. This procedure
was repeated four times. Cell debris were removed by cen-
trifugation at 400 × g for 20 min. (3) Pulsing with ITC pre-
pared at a concentration of 4.5 × 106 cells/well in 0.5 ml
RPMI-1640 medium and subjected to 1 × 104 Rads of
irradiation [15]. All methods employed a tumor:DC ratio of
3:1 and incubation at 37 °C for 24 h.
T cell priming by Ag-loaded autologous DCs
Frozen PBMCs were thawed, resuspended in complete
medium, and cultured overnight in a T25 flask (Eppendorf).
Peripheral blood lymphocytes (PBLs) were partially purified
by negative depletion from the nonadherent fraction of
PBMCs after removal of monocytes by adhesion to the cul-
ture flask. PBLs were seeded in a round-bottom 96-well
plate at 2 × 105 cells/well. The three different Ag-loaded
DC preparations were added to autologous PBLs at a ratio
of 1:20. After 1 week, a second identical stimulation was
performed. Half of the medium was replaced with fresh
medium containing 20 U/ml IL-2 twice per week. All ex-
periments were performed in triplicate. PBLs alone were
used as a control. The cultures were incubated at 37 °C
with 5 % CO2. CD4
+ and CD8+ T cell proliferation and
intracellular cytokine production in CD4+ T cells were
assessed by flow cytometry on day 6 after the second stimu-
lation by surface and intracellular staining.
In vitro induction of TAA-specific CTL responses by
tumor-derived Ag-loaded DCs
The Ag-loaded DCs prepared by different methods were
compared for their ability to stimulate CTL responses.
After Ag loading and maturation, the DCs (stimulators)
were added to PBLs (autologous responders to the DCs)
at a ratio of 1:20 in a round bottom 96-well plate.
Unpulsed mature DCs were used as a control. After
1 week, a second identical stimulation was performed.
Half of the medium was replaced with fresh medium
containing 20 U/ml IL-2, twice per week. On day 6,
PBLs were harvested and assessed for CTL activity. The
targets used for the CTL assay were SNU899-derived
lysate-pulsed immature DCs autologous to the CTLs.
These DC were not mature, unlike those used for CTL
stimulation, because immature Ag-pulsed DCs are
susceptible to CTL-mediated killing, whereas mature
DCs are protected from lysis [19].
For CTL assays, targets were labeled with 5 μM 5,6-car-
boxyfluorescein diacetate succinimidyl ester (eBioscience,
San Diego, CA, USA) for 10 min in the dark at room
temperature, and applied at an effector:target (E:T) ratio
of 10:1 using 2 × 104 target cells/well in a round-bottom
96-well plate. In parallel, target cells were incubated alone
to measure basal apoptosis. Cells were incubated for 6 h
at 37 °C with 5 % CO2. Cytotoxicity was assessed by flow
cytometry with annexin V and 7-aminoactinomycin D (7-
AAD) staining [20].
Flow cytometry and antibodies
DC phenotypes were determined using the following
anti-human monoclonal antibodies: anti-CD1a-PE-Cy7,
anti-CD83-FITC, anti-HLA-DR-eFluor 450, anti-CD80-
PE-Cy5, anti-CD86-PE, and anti-CD40-APC. On day 6,
PBLs were harvested and stained with the following
anti-human monoclonal antibodies: anti-CD3-eFluor 450,
anti-CD4-FITC, and anti-CD8a- PE-Cy7 for surface stain-
ing; anti-interferon (IFN)-γ-APC-eFluor780, anti-IL-2-PE-
Cy7, and anti-tumor necrosis factor (TNF)-α-Alexa Fluor
700 for intracellular staining. Soluble anti-CD3 (OKT3,
0.5 μg/ml) and anti-CD28 (CD28.2, 2 μg/ml) monoclonal
antibodies were used for in vitro activation of T cells. All
antibodies and isotype controls were purchased from
eBioscience. Samples were analyzed using a flow cyt-
ometer (LSRFortessa, BD, Franklin Lakes, NJ, USA). To
examine apoptosis, target DCs were stained with APC-
annexin V and 7-AAD (BD), and analyzed using a FACS-
CantoII flow cytometer (BD). Data were processed using
the accompanying software (FACSDiva, BD).
Statistical analysis
Experiments were repeated at least twice. Statistical analysis
was carried out using SPSS version 13.0 software (IBM,
Chicago, IL, USA) for Windows. Data are expressed as
means and standard deviation (SD). Differences between
the means were compared using Student’s t-test. A differ-
ence between two variables was considered significant
when the two-tailed P value < 0.05 (95 % confidence level).
Results
Effect of different Ag-loading strategies on DCs
CD14+ cells were purified from PBMCs using CD14
MicroBeads. Upon treatment with GM-CSF and IL-4, the
majority of cells formed clusters, displayed typical den-
dritic morphology, and became CD1a+ (94.1–99.7 %),
which are indicative of a DC phenotype. On day 6, DCs
were treated for 24 h with SNU899-derived Ags using
three strategies. Compared with control DCs, DC-TCS or
DC-TSL formed larger and more aggregates, whereas the
DC cell density was relatively high after co-culturing with
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ITC (Fig. 1). DC maturation was induced on day 7 by
treatment with 1 μg/ml LPS for 2 days, and evaluated by
flow cytometry (Fig. 2). DC-TSL expressed the highest
levels of HLA-DR and CD86. DC-ITC also had elevated
HLA-DR expression, but expressed the lowest levels of
co-stimulatory molecules (CD80, CD86, and CD40).
HLA-DR expression on the surface of DC-TCS remained
at the same level as that in DC controls.
These data suggest that TSLs and ITC may provide
much more Ags than SNU899 culture supernatant for
presentation by DCs. Furthermore, tumor cell Ags may
affect DC activation in response to maturation signals
such as LPS. Interestingly, tumor Ags promoted cluster
formation and thus may contribute to DC proliferation.
Induction of TAA-specific T cell responses by Ag-loaded
DCs
Generation of TAA-specific T cells by the three DC-
loading strategies were compared by flow cytometry
after two stimulations with Ag-loaded mature DCs. In-
duction of TAA-specific T cells by Ag-loaded DCs was
dependent on the Ag-priming strategy, as indicated by
the increased numbers of CD4+(Fig. 3a) and CD8+
(Fig. 3b) induced by DC-TSL, compared with DC-TCS
or DC-ITC. This result strongly suggests that DC loading
induces differential MHC class I and II cross-presentation
of TAAs to T cells. However, this observation differs from
previous reports [15, 21]. The stressed lysis strategy of the
tumor cell line SNU899 resulted in the highest efficiency
of T cell activation, which reflected the higher levels of
TAAs after loading.
Analysis of TAA-specific Th1 cytokine response induced
by Ag-loaded DCs
Cytokines visualized by intracellular staining were
used to confirm the effect of Ag priming on Th1 re-
sponses (Fig. 4). Reactive lymphocytes stimulated by
Ag-loaded DC lysate showed a higher proportion of
IFN-γ and IL-2-secreting CD4+ T cells than those
stimulated by DC controls, but a lower ratio of TNF-
α-secreting CD4+ T cells. DC-TCS reduced all Th1 cy-
tokines (IFN-γ, IL-2, and TNF-α) secreted by CD4+ T
cells. The irradiation strategy resulted in a decrease in
the proportion of cells secreting IFN-γ and IL-2, but
increased those secreting TNF-α (Fig. 4a). Further-
more, significant numbers of IFN-γ and IL-2-secreting
CD4+ T cells were induced by DC-TSL (Fig. 4b), which
could be attributed to the increased proportion of
cytokine-secreting CD4+ T cells (Fig. 4a) and increased
number of TAA-specific CD4+ T cells (Fig. 3a). How-
ever, TCS and ITC strategies inhibited the generation
of Th1 cytokine-secreting CD4+ T cells.
These data suggest strongly that SNU899 cell-derived
stressed lysate Ags induce a more efficient TAA-
specific Th1 cytokine response, and may be the optimal
Ag loading method.
Fig. 1 Photomicrographs of DC cultures (4×). DCs cultured for 5 days were pulsed for 24 h with SNU899 Ags using three different methods. All
methods employed a tumor:DC ratio of 3:1. Compared with the DC control (≤200 μm), DC-TCS or DC-TSLs appeared to form larger adherent
aggregates (>200 μm), whereas DC-ITC had a higher density
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Induction of TAA-specific CTL responses
The three types of Ag-loaded DCs were used as stimulators
for autologous PBLs to compare their efficacy for CTL
stimulation. SNU899-derived lysate-pulsed immature DCs
autologous to the CTLs were used as target cells for recog-
nition of their MHC-antigen complexes by reactive CTLs.
The ratio of apoptotic target cells was determined with flow
cytometry by subtraction of basal level apoptosis. CTLs
stimulated by DC-TSL resulted in a higher ratio of apop-
totic target cells (Fig. 5a). Statistical analysis showed that
DC-TSL were more effective at stimulating CTL responses
than DC-TCS (36.9 ± 0.6 % and 32.1 ± 5.4 %, respectively;
Fig. 5b). DC-ITC induced a much lower CTL response
(24.6 ± 3.0 %; Fig. 5b) compared with DC-TSL (P = 0.03).
Discussion
DC vaccines take advantage of the potent antigen-
presenting capacity of DCs to stimulate primary and
secondary T and B cell immune responses. Clinical tri-
als have been performed for several advanced cancers
such as melanoma and renal, prostate, and colon can-
cers, which have shown encouraging results [5–7]. DC
vaccines targeting mutated proteins in the p53 pathway
[22] and human papilloma virus peptides have been
produced for the treatment of HNSCC [22, 23]. These
TAA-loaded DCs stimulate immunological and clinical
responses in certain patients. However, a significant
proportion of patients remain unresponsive to immu-
nomodulatory therapy.
Unlike specific TAAs, whole tumor cells or their deriv-
atives may better apply to various tumors for which few
or no defined tumor-specific antigens are available, such
Fig. 2 Phenotypes of DCs loaded with SNU899-derived Ags by different
methods. To induce maturation, control DCs and SNU899-derived
Ag-loaded DCs were treated with 1 μg/ml LPS for 48 h. A DC maturation
marker (CD83), MHC-II molecule (HLA-DR), and co-stimulatory molecules
(CD80, CD86, and CD40) were measured by flow cytometry. DC-TSL
expressed the highest level of HLA-DR and CD86. DC-ITC also
exhibited elevated HLA-DR expression, but expressed the lowest
level of co-stimulatory molecules. HLA-DR expression on the surface of
DC-TCSs remained at the same level as in unpulsed DCs. Data shown
are representative of three experiments
Fig. 3 Induction of TAA-specific T cell responses by DCs loaded with SNU899-derived Ags by various methods. a Induction of TAA-specific CD4+
T cells. TAA-loaded mature DCs were added to autologous PBLs at a ratio of 1:20. On day 6 after the second stimulation, the number of CD4+ T
cells was assessed by flow cytometry. The methods used to load the DCs induced differential class II cross-presentation of TAAs to the T cells.
However, the stressed lysis strategy resulted in the highest efficiency of T cell activation, reflecting a higher level of TAAs after loading. b Induction of
TAA-specific CD8+ T cells. Similar to the cross-presentation by MHC class II, TCL-DCs were also much more efficient at cross-presentation of TAAs by
MHC-I, and thus T cell activation, than DC-TCS or DC-ITC. Data are mean values ± SD of triplicate determinations. Statistical comparisons were performed
using Student’s t-test. *P< 0.05 vs. DC control; **P< 0.01 vs. DC control
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as for laryngeal cancer. Furthermore, whole tumor cell
immunizations result in polyvalent stimulation of both
CD4+ Th cells and CD8+ CTLs against a broad range of
Ags. Therefore, DCs loaded with Ags in this manner
may be used to treat laryngeal cancer.
Among the current methods for pulsing DCs with
whole tumor-derived materials, tumor cell lysates, which
are prepared by repeated cycles of freezing and thawing
with solid debris removed by centrifugation, have been
widely applied in early stage clinical trials. However, an
increasing number of trials have shown that the immune
response elicited by DC-TSL does not generate a suffi-
cient antitumor potency [10, 13, 14]. Recently, several
studies have demonstrated that freeze-thawed lysates
suppress DC maturation and function in vitro, and are
ineffective for loading DCs for therapies in vivo [15, 16].
Our preliminary study also suggests that DCs cultured
in the presence of human laryngeal cancer-derived
lysates decreased surface expression of B7–1, B7–2, and
MHC molecules, and inhibit T cell proliferation (data
not shown). Potential explanations for these findings
include the use of different tumor stains, alternate
Fig. 4 Induction of TAA-specific Th1 cytokines by three DC Ag-loading strategies. DCs were pulsed with either SNU899 tumor cell supernatant,
stressed lysate, or irradiated tumor cells. Autologous PBLs were stimulated twice with Ag-loaded mature DCs. On day 6 after the second stimulation,
production of IFN-γ, IL-2, and TNF-α by TAA-specific CD4+ T cells was detected by intracellular staining. a Numbers indicate the percentage of gated
CD4+ T cells. When PBLs were stimulated by TCL-DCs, the percentage of IFN-γ and IL-2-secreting CD4+ T cells was higher than in other groups, whereas
DC-ITC induced a higher percentage of TNF-α-secreting CD4+ T cells. b Number of Th1 cytokine (IFN-γ, IL-2, and TNF-α)-positive cells were assessed by
flow cytometry. Compared with the DC control, TCL-DCs stimulated an effective TAA-specific T cell response, whereas DC-TCS and DC-ITC inhibited
such responses. These results clearly demonstrate the efficacy of stressed lysis as a means of tumor cell preparation for DC loading. Data are mean
values ± SD of triplicate determinations. Statistical comparisons were performed using Student’s t-test. *P < 0.05 vs. DC control; **P < 0.01 vs. DC control
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vaccination schedules, and the use of DCs at various
stages of maturity [10].
To elicit an effective immune response, we used three
strategies for loading DCs with tumor-derived Ags and
compared their ability to stimulate CTL activity. The
loading strategies included using DC-TCS, DC-TSL, and
DC-ITC. Our results show that human laryngeal cancer-
derived TSL was an effective TAA source for pulsing
DCs. DC-TSL not only induced the most potent CTL
activity, but also induced the strongest MHC class I
TAA-specific T response (proliferation of TAA-specific
CD8+ T cells), the highest expansion of TAA-specific T
cells (based on the number of TAA-specific T cells), and
the strongest Th1 cytokine response (elevated levels of
IFN-γ and IL-2 production). Interestingly, DC-TSL in-
duced both class I and class II TAA-specific responses,
suggesting that DC-TSL are capable of both class I and
II cross-presentation. These results emphasize that the
choice of Ag-loading strategy is critical to the strength
of the immune response.
We identified alterations in the DC phenotype after
treatment with tumor-derived Ags. DC-TSL expressed the
highest level of HLA-DR and CD86, whereas DC-ITC also
had elevated HLA-DR expression but expressed the lowest
levels of co-stimulatory molecules (CD80, CD86, and
CD40). HLA-DR expression on the surface of DC-TCS
remained at the same level as that in DC controls. A
significant body of evidence has shown that stimulating a
stress response in tumor cells increases the production of
HSPs, which may expand the repertoire of TAAs and
enhance TAA delivery to professional antigen-presenting
cells (APCs) [17, 24, 25]. Additionally, stress-induced HSPs
stimulate DCs and induce APC cytokine and chemokine
secretion [26–29]. Our findings support the idea that the
stressed lysis strategy has advantages by providing a larger
TAA repertoire. Moreover, elevation of co-stimulatory
molecules such as CD86 may enhance DC capacity to
prime T cell responses. In contrast, cell culture superna-
tants may not contain sufficient or adequate Ags secreted
by laryngeal cancer cells. Although one study reported that
DC antigen presenting function can be improved by super-
natants from retinoblastoma cells [18], it is not surprising
that laryngeal cancer has a distinct tumor milieu to interact
with DCs. LSCC cells may evade the host immune system
through manipulation of their own immunogenicity, pro-
duction of immunosuppressive mediators, and promotion
of immunomodulatory cell types [30–32]. Consistent with
some studies [33], there was a reduction of CD80, CD86,
and CD40 in DC-ITC. Various mechanisms through which
intact tumor cells suppress DC functions have been
described, including cytokines (e.g., TGF-β, IL-10, and vas-
cular endothelial growth factor), ceramide [34], and other
tumor-derived lipids [35]. However, a complete under-
standing of the mechanisms by which DC suppression
functions will require additional study.
Studies have shown that CD8+ and Th1 cells play an
important role in controlling tumor growth. For example,
CD8+ T cells mediate antitumor immunity [36]. Th1 cells, a
subset of CD4+ T cells, constitutively express IFN-γ and
TNF-α, and play a role in priming tumor-specific CTLs
through the release of soluble IL-2 in the proximity of
CTLs [37]. In addition, induction of MHC class I tumor-
specific immunity requires epitope linkage between Th1
and CTL epitopes, which is important for CTL induction
[38]. In the current study, DC-TSL pulsing was the only
effective method to prime CD8+ and CD4+ T cells. This
result indicates that a TSL is not only processed for MHC
class I presentation, but also cross-presented by the MHC
class II pathway, consistent with the elevation of class II
molecules (HLA-DR) on DC-TSL. Further experimentation
showed that both the percentage and number of Th1 cells
(including IFN-γ- and IL-2-secreting cells) were increased
in T cell and DC-TSL co-culture, which strongly supports
the choice of TSL-pulsed as a promising CTL activator
against laryngeal cancer. It is worth noting that the stronger
and broader T cell response induced by DC-TSL may bene-
fit from production of HSPs, such as HSP70 and HSP90
[39, 40], whose antitumor activity is exerted through
Fig. 5 Induction of TAA-specific CTL activity by three DC Ag-loading
strategies. a Ag-loaded DCs were used as stimulators of autologous
PBLs to compare their efficacy in CTL stimulation against Ag-pulsed
target cells. PBLs and DCs were generated from a single donor. Data
are from one representative experiment. b TAA-specific cytotoxicity
was determined by flow cytometry. Data are the mean percentages
of cytotoxicity ± SD of triplicate determinations. TCL-DCs induced a
more potent CTL response compared with DC-ITC as shown by the
increased cytotoxicity from SNU899-derived Ag-pulsed autologous
DCs used as targets at a 10:1 E:T. Statistical comparisons were performed
using Student’s t-test
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various mechanisms. The inefficiency of DC-ITC to induce
Ag-specific T cell responses can be explained by the ineffi-
cient cross-presentation of TAAs by DCs that express low
levels of co-stimulatory molecules. Although apoptotic
tumor cells induced by irradiation effectively prime APCs
in vitro, they likely cannot stimulate DCs to generate an
antitumor immune response in the absence of additional
maturation [41].
The incompetence of DC-TCS, which express low
levels of MHC molecules (e.g., HLA-DR) and maturation
markers (e.g., CD83), may result from inhibition by the
tumor milieu and fewer laryngeal cancer cell-secreted
Ags. Although CTL activity of DC-TCS was lower than
that of DC-TSL, which induced the highest as expected,
there was no significant difference between them. The
increased CTL activity of DC-TCS-stimulated PBLs may
be due to more active natural killer and natural killer T
cells, which comprise the majority of non-CD8 T lympho-
cyte effector cells [42]. Additionally, to ensure that the
Ag-MHC complex was recognized by CTLs, we used Ag-
pulsed DCs as the source of MHC-matched target cells,
which may not accurately reflect tumor cell susceptibility
to CTL lysis [43].
Conclusions
We demonstrate that a heat-treated TSL is an effective
source of TAAs for pulsing DCs to treat human LSCC.
DC-TSL induced the greatest expansion of TAA-specific T
cells, the strongest Th1 cytokine response, and the most
potent CTL activity, whereas DC-TCS or DC-ITC inhibited
T cell activation and induced only a certain extent of CTL
activity. Although the efficacy of this loading strategy needs
to be tested further, such as in a setting whereby the CTL
response could be tested using autologous laryngeal cancer
cells, we have provided an encouraging alternative strategy
for DC-based immunotherapy for laryngeal cancer.
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